Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22824806 | 0.88 | NLRP3 (0.47) | NLRP3 | |
| SCHEMBL20757244 | 0.79 | NLRP3 (0.49) | NLRP3 | |
| SCHEMBL20757609 | 0.72 | TAS2R14 (0.46) | NLRP3 | |
| SCHEMBL22824586 | 0.68 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL24295772 | 0.68 | — | — | |
| SCHEMBL23329024 | 0.68 | HTR6 (0.32) | — | |
| SCHEMBL23329278 | 0.67 | — | — | |
| SCHEMBL30092353 | 0.66 | NLRP3 (0.39) | NLRP3 | |
| SCHEMBL23310480 | 0.65 | MEN1 (0.36) | — | |
| SCHEMBL24295351 | 0.65 | CNR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-01-03 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047302-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, CBR3 | NLRP3 1/4885 |
| US-20200399243-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885 |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, PYCARD | NLRP3 1/4885 |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885 |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | NLRP3 1/4885 |
| US-11530200-B2 | Compounds | NLRP3, NOD1, NLRP1 | NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.